166 related articles for article (PubMed ID: 12796361)
1. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Hirasawa A; Saito-Ohara F; Inoue J; Aoki D; Susumu N; Yokoyama T; Nozawa S; Inazawa J; Imoto I
Clin Cancer Res; 2003 Jun; 9(6):1995-2004. PubMed ID: 12796361
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
[TBL] [Abstract][Full Text] [Related]
3. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
4. PPM1D is a potential target for 17q gain in neuroblastoma.
Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
[TBL] [Abstract][Full Text] [Related]
5. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas.
Ho CM; Lin MC; Huang SH; Huang CJ; Lai HC; Chien TY; Chang SF
Gynecol Oncol; 2009 Feb; 112(2):307-13. PubMed ID: 19007975
[TBL] [Abstract][Full Text] [Related]
6. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Mendrzyk F; Radlwimmer B; Joos S; Kokocinski F; Benner A; Stange DE; Neben K; Fiegler H; Carter NP; Reifenberger G; Korshunov A; Lichter P
J Clin Oncol; 2005 Dec; 23(34):8853-62. PubMed ID: 16314645
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma.
Ho CM; Huang CJ; Huang CY; Wu YY; Chang SF; Cheng WF
Mol Cancer; 2012 Aug; 11():53. PubMed ID: 22871047
[TBL] [Abstract][Full Text] [Related]
9. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
10. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
Kresse SH; Skårn M; Ohnstad HO; Namløs HM; Bjerkehagen B; Myklebost O; Meza-Zepeda LA
Mol Cancer; 2008 Jun; 7():48. PubMed ID: 18522746
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
12. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.
Watanabe T; Imoto I; Kosugi Y; Ishiwata I; Inoue S; Takayama M; Sato A; Inazawa J
Gynecol Oncol; 2001 May; 81(2):172-7. PubMed ID: 11330945
[TBL] [Abstract][Full Text] [Related]
13. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival.
Li B; Jin H; Yu Y; Gu C; Zhou X; Zhao N; Feng Y
Int J Gynecol Cancer; 2009 Nov; 19(8):1347-52. PubMed ID: 20009888
[TBL] [Abstract][Full Text] [Related]
14. Ovarian clear cell adenocarcinoma: a continuing enigma.
Tan DS; Kaye S
J Clin Pathol; 2007 Apr; 60(4):355-60. PubMed ID: 17018684
[TBL] [Abstract][Full Text] [Related]
15. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
16. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
Birrer MJ; Johnson ME; Hao K; Wong KK; Park DC; Bell A; Welch WR; Berkowitz RS; Mok SC
J Clin Oncol; 2007 Jun; 25(16):2281-7. PubMed ID: 17538174
[TBL] [Abstract][Full Text] [Related]
17. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
18. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
[TBL] [Abstract][Full Text] [Related]
19. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors].
Zhang CY; Guo HY; Li H; Wen HW; Liang XD; Qiao J
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):688-91. PubMed ID: 23159083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
